NCT01265433 · OUTCOME

1-year Progression-free Survival

Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy · Source last updated 2024-10-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

What was measured

Progression free survival (PFS) rate will be calculated from the time of randomization to first evidence of disease recurrence or death of any cause.

Galinpepimut-S + Montanide + GM-CSF

Montanide + GM-CSF

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Galinpepimut-S	20
Control	21

Source class 1

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Galinpepimut-S	44	Not reported	Not reported	Not reported	Not reported
Control	33	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

Progression free survival (PFS) rate will be calculated from the time of randomization to first evidence of disease recurrence or death of any cause.

groups

param Type

NUMBER

reporting Status

POSTED

time Frame

1 year

title

1-year Progression-free Survival

type

PRIMARY

unit Of Measure

percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice